SavedAdd your journal

Journals / Romatizma Dergisi / 2006 / Cilt: 21 - Sayı: 2

Methotrexate and leflunomide in the treatment of rheumatoid arthritis

Romatoid artrit tedavisinde metotreksat ve leflunomid

Hatice BODUR
Pages
60–66
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review the efficacy, safety, mono and combination therapy of these drugs have been discussed. (Rheumatism 2006; 21: 60-6)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The treatment of rheumatoid arthritis has changed in the last ten years.
📊
Key Findings & Data:Methotrexate is an antimetabolite drug and commonly used as the first disease modifying antirheumatic drug (DMARD).
💡
Conclusion & Impact:In this review the efficacy, safety, mono and combination therapy of these drugs have been discussed. (Rheumatism 2006; 21: 60-6)
🔬Design:Review & Systematic Survey
📍Scope:2006 Verileri
⚙️Variables:İlaç kombinasyonları · Methotreksat · Artrit

Abstract

The treatment of rheumatoid arthritis has changed in the last ten years. Methotrexate is an antimetabolite drug and commonly used as the first disease modifying antirheumatic drug (DMARD). Its clinical efficacy and safety profile has been documented and it slows the development of radiological erosions. Leflunomide is also an antimetabolite drug and relatively new. In this review the efficacy, safety, mono and combination therapy of these drugs have been discussed. (Rheumatism 2006; 21: 60-6)

Özet

Romatoid Artrit tedavisi son on yılda değişiklik göstermiştir. Metotreksat antimetabolit bir ilaçtır ve sıklıkla ilk tercih edilen hastalık modifiye edici ilaçtır. Klinik etkinlik ve güvenilirlik profili tanımlanmıştır ve radyolojik erozyon gelişmesini yavaşlatır. Leflunomid de antimetabolit bir ilaçtır ve nispeten yenidir. Bu derlemede bu ilaçların etkinlik, güvenilirlik, mono ve kombinasyon tedavisi tartışılmıştır. (Romatizma-2006; 21: 60-6)

🔖

Cite This Article

BODUR, H. (2006). Methotrexate and leflunomide in the treatment of rheumatoid arthritis. Romatizma Dergisi, Cilt: 21 - Sayı: 2, 60–66. https://ajindex.com/articles/305917

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Laan R FJM, van Riel P LCM, van de Putte L BA. Leflunomide and methotrexate. Current Opinion in Rheumatology 2001;13:159-63
  2. O'Dell JR. Methotrexate, leflunomide, and combination therapies. In: Harris ED, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB (eds) Kelley's Textbook of Rheumatology. Seventh edition. Philadelphia, Elsevier Saunders, 2005: 900-19
  3. Simon LS. The treatment of rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 2004; 18: 507-38
  4. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001; 134:695-706
  5. O'Dell JR. How is it best to treat early rheumatoid arthritis patients Best Practice & Research Clinical Rheumatology 2001; 15: 125-37
  6. Ranganathan P, Eisen S, Yokohama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:4-9
  7. Nurmohamed MT, Dijkmans B AC. Efficacy, tolerability and cost effectiveness of disease modifying antirheumatic dugsand biologic agents in rheumatoid arthritis. Drugs 2005; 65:661-94
  8. Bresnihan B. Treating early rheumatoid athritis in the younger patients. J Rheumatol 2001;28:4-9
  9. Li EK, Tam L-S, Tomlinson B. Leflunomid in the treatment of rheumtaoid arthritis. Clinical Therapeutics 2004;26: 447-59
  10. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, et al. Leflunomid for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003;30: 1182-90
  11. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al. Combination leflunomid and Methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy:Open-label extension of a randomized, double blind, placebo controlled trial. J Rheumatol 2004;31: 1521-31
  12. Emery P, Cannon G, Holden W, et al. Results from a cohort of over 40,000 rheumatoid arthritis (RA) patients: Adverse event (AE) profiles of leflunomid (LEF), methotrexate (MTX) and other disease-modifying antirheumatic drugs (DMARDs). Ann Rheum Dis 2002; 61(Suppl.1): 42
  13. Madison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D, et al. Leflunomid in rheumatoid arthritis: recommendations through a process of consensus. Rheumatol 2005; 44:280-6
  14. Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. Newer disease modifying antirheumatic drugs and the risk of serious hepatic adverse events in pat